CLOs on the Move

Aktis Oncology

www.aktisoncology.com

 
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Human Longevity

Human Longevity, Inc. ™ (HLI) is the genomics-based, health intelligence company creating the world`s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. Our DNA determines so much about each of us, but other factors can also influence our health. HLI is focused on compiling and analyzing more genotypic and phenotypic data because the combination of both enables us —to generate unprecedented insights and accelerate our understanding into what makes us who we are and what we can change for a life better lived.

Spine Vision

Spine Vision is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Sofie Biosciences

Sofie Biosciences is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perseus

Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting.